newsfilter
← Earnings
Earnings Releases·

NeoGenomics — Third Quarter 2026 Earnings Summary

  • Revenue rose 11% year-over-year to $209 million, driven by a 29% surge in Next-Generation Sequencing (NGS) revenue, while adjusted EBITDA jumped 53% to $19 million and net loss narrowed 72% to $8 million.
  • Full-year 2026 guidance was raised across the board: revenue to $807–$809 million, adjusted EBITDA to approximately $60 million, and net loss narrowed to $(30)–$(32) million.
  • Strategic leadership succession was announced with Warren Stone set to become CEO effective January 4, 2027, replacing Tony Zook who will transition to Executive Chairman.
  • Capital allocation included $25 million in common stock repurchases over the nine months ended September 30, 2026, alongside a $11.2 million gain on debt extinguishment.
Company
NEOGENOMICS INC
Sector
Healthcare
Industry
Diagnostics & Research